In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 2, 1999, Pages 223-228

  Del Poeta, Maurizio ^a,b   Bixel, Amy S ^a   Barchiesi, Francesco ^b   Tidwell, Richard R ^c   Boykin, David ^d   Scalise, Giorgio ^b   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AROMATIC COMPOUND; FLUCONAZOLE;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CRYPTOCOCCUS NEOFORMANS; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; STRUCTURE ACTIVITY RELATION; YEAST;

ANTIFUNGAL AGENTS; BENZIMIDAZOLES; CANDIDA; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; FURANS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0032793322     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.2.223     Document Type: Article

References (26)

1. Wheat, L. J. (1994). Fungal infections in the immunocompromised host. In Clinical Approach to Infection in the Compromised Host, (Rubin, R. H. &Young, L. S., Eds), pp. 211-37. Plenum, New York, NY.
2. Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A. & Perfect, J. R. (1993). Correlation of in-vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 3, 2449-53.
3. Fox, R., Neal, K. R., Leen, C. L. S., Ellis, M. E. & Mandal, B. K. (1991). Fluconazole resistant Candida in AIDS. Journal of Infection 22, 201-4.
4. Pfaller, M. A., Rhine-Chalberg, A. J., Redding, S. W., Smith, J., Farinacci, G., Fothergill, A. W. et al. (1994). Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from AIDS and oral candidiasis. Journal of Clinical Microbiology 32, 59-64.
5. Willocks, L., Leen, C. L. S., Brettle, R. P., Urquhart, D., Russel, T. B. & Milne, L. J. R. (1991). Fluconazole resistance in AIDS patients. Journal of Antimicrobial Chemotherapy 28, 937-9.
6. Bell, C. A., Cory, M., Fairley, T. A., Hall, J. E. & Tidwell, R. R. (1991). Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity. Antimicrobial Agents and Chemotherapy 35, 1099-107.
7. Bell, C. A., Dykstra, C. C., Naiman, N. A., Cory, M., Fairley, T. A. & Tidwell, R. R. (1993). Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. Antimicrobial Agents and Chemotherapy 37, 2668-73.
8. Lindsay, D. S., Blagburn, B. L., Hall, J. E. & Tidwell, R. R. (1991). Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures. Antimicrobial Agents and Chemotherapy 35, 1914-6.
9. Bell, C. A., Hall, J. E., Kyle, D. E., Grogl, M., Ohemeng, K. A., Allen, M. A. et al. (1990). Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrobial Agents and Chemotherapy 34, 1381-6.
10. Tidwell, R. R. & Bell, C. A. (1993). Pentamidine and related compounds in the treatment of Pneumocystis carinii infection. In Pentamidine and Related Compounds in the Treatment of Pneumocystis carinii Infection, (Walzer, P. D., Ed.), pp. 561-83. Marcel Dekker, New York, NY.
11. Tidwell, R. R., Jones, S. K., Geratz, J. D., Ohemeng, K. A., Bell, C. A., Berger, B. J. et al. (1990). Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Annals of the New York Academy of Sciences 616, 421-41.
12. Tidwell, R. R., Jones, S. K., Naiman, N. A., Berger, L. C., Brake, W. B., Dykstra, C. C. et al. (1993). Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 37, 1713-6.
13. Keku, T. O., Seed, J. R. & Tidwell, R. R. (1995). The in-vitro HL-60 cell - Trypanosoma brucei rhodesiense culture system: a rapid in-vitro drug screen. Tropical Medicine and Parasitology 46, 258-62.
14. Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S. K., Tidwell, R. R., Czarny, A. et al. (1998). Structure-in vitro activity relationships of pentamidine analogous and dication substituted bis-benzimidazoles as new antifungal agents. Antimicrobial Agents and Chemotherapy 42, 2495-502.
15. Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S. K., Tidwell, R. R., Kumar, A., et al. (1998). In vitro antifungal activity of a series of dication substitute carbazoles, furans and benzimidazoles. Antimicrobial Agents and Chemotherapy 42, 2503-10.
16. Boykin, E. W., Kumar, A., Spychala, J., Zhou, M., Lombardy, R. J., Wilson, W. D. et al. (1995). Dicationic diarylfurans as anti-Pneumocystis carinii agents. Journal of Medicinal Chemistry 38, 912-6.
17. Barchiesi, F., Falconi Di Francesco, L., Compagnucci, P., Arzeni, D., Cirioni, O. & Scalise, G. (1997). Genotypic identification of sequential Candida albicans isolates from AIDS patients by Polymerase Chain Reaction techniques. European Journal of Clinical Microbiology and Infectious Diseases 16, 601-5.
18. White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 41, 1482-7.
19. White, T. C. (1997). The presence of an R467K amino acid substitution and loss of allelic variation correlate with azole-resistant lanosterol 14-α demethylase in Candida albicans. Antimicrobial Agents and Chemotherapy 41, 1488-94.
20. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Susceptibility Testing of Yeasts: Accepted Standard M27-A. NCCLS, Wayne, PA.
21. McGinnis, M. R. (1980). Susceptibility testing and bioassay procedure. In Laboratory Handbook of Medical Mycology, p. 431. Academic Press, New York, NY.
22. Boykin, D. W., Kumar Xiao, A. G., Wilson, W. D., Bender, B. C., McCurdy, D. R., Hall, J. E. et al. (1998). 2,5-Bis[4-(N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents. Journal of Medicinal Chemistry 41, 124-9.
23. Blagburn, B. L., Sundermann, C. A., Lindsay, D. S., Hall, J. E. & Tidwell, R. R. (1991). Inhibition of Cryptosporidium parvum in neonatal Hsd: (ICR)BR Swiss mice by polyether ionophores and aromatic amidines. Antimicrobial Agents and Chemotherapy 35, 1520-3.
24. Dykstra, C. C., McClernon, D. R., Elwell, L. P. & Tidwell, R. R. (1994). Selective inhibition of topoisomerases from Pneumocystis carinii versus topoisomerases from mammalian cells. Antimicrobial Agents and Chemotherapy 38, 1890-8.
25. Jones, S. K., Hall, J. E., Allen, M. A., Morrison, S. D., Ohemeng, K. A., Reddy, V. V. et al. (1990). Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 3, 1026-30.
26. Del Poeta, M., Toffaletti, D. L., Rude, T. H., Dykstra, C. C., Heitman, J. & Perfect, J. R. (1999). Topoisomerase I is essential in Cryptococcus neoformans: role in pathobiology and as an antifungal target. Genetics 152, 167-78.